chartexchange

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer

GlobeNewswire Inc. | Nov 18, 2026 8:00 AM EST

Telomir selects Linical to advance FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer, targeting Q1 2027 clinical initiation.

Read original article